Advancements in Radiotherapy for Oligometastatic Pancreatic Cancer
Recent developments in the treatment of oligometastatic pancreatic ductal adenocarcinoma (PDAC) indicate that the role of radiotherapy is progressing beyond palliative care to become a key component in multidisciplinary treatment strategies. A narrative review of recent studies has highlighted this evolving role, emphasizing the potential of stereotactic body radiotherapy (SBRT) as a disease-modifying intervention in PDAC.
SBRT has been established as a standard treatment for conditions like oligometastatic lung and prostate cancer, yet its application in pancreatic cancer remains complex due to unique challenges associated with tumor biology and anatomical constraints. Despite the obstacles and lack of randomized evidence, promising results have been noted. Retrospective data suggest impressive 1-year local control rates for primary pancreatic tumors, lung metastases, and lymph node metastases, achieving 70-80%, 85-95%, and >95% control rates, respectively, with SBRT-based consolidative therapy leading to a median overall survival of 12-18 months.
Emerging biomarkers such as circulating tumor DNA (ctDNA) dynamics, KRAS mutation subtypes, and transcriptomic classifiers complement newer technologies like MR-guided adaptive SBRT and proton therapy, offering hope for improved therapeutic outcomes. The potential of the TREX1/cGAS-STING axis for combining SBRT with immune checkpoint inhibitors offers additional therapeutic pathways, though quality-of-life data remain limited.
The shift of SBRT from palliative care to a multidisciplinary role necessitates validation through pancreas-specific randomized trials aimed at optimizing patient selection based on biomarkers and reported outcomes. The prospect of biomarker-driven patient selection integrated with patient-reported outcomes is crucial for defining SBRT’s role in treating oligometastatic PDAC effectively.
The integration of systemic therapies, particularly immunotherapy, with SBRT is a promising area of research. While immunotherapy, particularly immune checkpoint inhibitors, has shown limited efficacy in PDAC due to the cancer's immunosuppressive microenvironment, radiotherapy's inherent immunogenic potential offers a rationale for combined treatments.
SBRT's role in oligometastatic PDAC demonstrates significant potential in altering the natural history of the disease, stepping beyond mere palliation toward extending patient outcomes through collaborative, multidisciplinary approaches. However, further research, particularly in the form of randomized controlled trials, is essential to fully realize this potential and refine the therapeutic strategy to maximize patient benefit and quality of life.